Novartis wants Japan to link drug price to patient outcomes

to The Nikkei in a recent interview. Japan has never implemented such a payment scheme. At issue is Kymriah, a new treatment for acute lymphoblastic leukemia in children and young adults. Kymriah in August became the first CAR-T cell therapy — one that …
( read original story …)


Related Post

China finance minister skips summit with Japan, Ko...
views 100
YOKOHAMA, Japan Chinese Finance Minister Xiao Jie ...
Japan finance minister vows to stick to fiscal yea...
views 88
TOKYO Japan must adhere to the government's goal t...
Five Bright Spots for Japan Banks Burdened by Nega...
views 89
That’s all welcome news for the Tokyo-based ...
MotoGP legend remains behind bars in Japan
views 89
Australian motorcycling great Wayne Gardner remain...
Team USA beats Japan, second at Tournament of Nati...
views 41
The U.S. women’s national soccer team won its seco...
Japan stocks higher at close of trade; Nikkei 225 ...
views 43
Investing.com – Japan stocks were higher after the...
Japan Post looking to buy Nomura’s stake in real e...
views 109
The government sold shares in Japan Post Holdings ...
Japan stocks to hit 21-year high in 2017 on weak y...
views 35
TOKYO (Reuters) - Japanese stocks are forecast to ...
Osaka University opens genome-editing research cen...
views 84
OSAKA – Osaka University has become the firs...
Japan offering free ramen to get older drivers off...
views 78
Here’s an appetizing offer. Police in Japan ...